This inventor holds 1 USPTO granted patent. Top assignee: Molecure S.a.. Active years: 2025.
Company Filing History:
Years Active: 2025
Title: Rafał Kozieł: Innovator in Therapeutic Applications
Introduction
Rafał Kozieł is a prominent inventor based in Lesznowola, Poland. He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic applications related to chitinase-like protein YKL-40. His innovative work has the potential to impact various medical treatments and diagnostics.
Latest Patents
Rafał Kozieł holds a patent for YKL-40 inhibitors and their therapeutic applications. This patent discloses assays for screening active compounds that interfere with the interaction between chitinase-like protein YKL-40 and chitin oligomers, as well as with heparan sulfate. The patent also identifies active compounds that serve as inhibitors of YKL-40, detailing their therapeutic applications and their use in biosensors for measuring YKL-40 levels in biological samples. He has 1 patent to his name.
Career Highlights
Kozieł is associated with Molecure S.A., a company focused on developing innovative therapies. His work at Molecure has allowed him to explore the therapeutic potential of YKL-40 inhibitors, contributing to advancements in the field of medicine.
Collaborations
Rafał Kozieł collaborates with notable colleagues, including Łukasz Krzemiński and Wojciech J Czestkowski. These collaborations enhance the research and development efforts within his field.
Conclusion
Rafał Kozieł is a key figure in the biotechnology sector, with a focus on therapeutic innovations related to YKL-40. His contributions through patents and collaborations are paving the way for future advancements in medical treatments.